27
October

08:00 AM BST

Clinical Operations

Name: Clinical Operations & Clinical Trial Supply Chain Strategy Meeting Europe 2026
Start: 2026-02-27T08:00
End: 2026-10-27T18:00
Location: Crowne Plaza, London Docklands

&

Clinical Trial Supply Chain

Strategy Meeting Europe 2026

Advancing Clinical Innovation: Connecting AI, Patients, Operations, and Supply Chains to Accelerate Trial Success.

Crowne Plaza London Docklands

Our Event Starts In

–
days

–
hours

–
minutes

–
seconds

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Clinical Operations Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s Clinical Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Clinical Operations professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Clinical Operations strategy meeting.

Abhishek Miglani

Head, Enterprise Platform, Senior Director Veeva & Global Clinical Operations Technology, Astellas

Alexander Fetkovsky

CEO SanaClis

Charmaine O’Neill

Vice President, Clinical Operations Vantage Biosciences & Axovia Therapeutics

David Holman

Head, Clinical Program Management 30 Technology

Deirdre Flaherty

Vice President, Development Project Strategy & Clinical Operations Alchemab Therapeutics Ltd

Dr. Apurba Mukherjee

Regional Medical Head, Intercontinental and JAK Regions Ferring Pharmaceuticals

Dr. Tony Lockett

Chief Medical Officer Nevrargenics Ltd.

Eamonn McArdle

Lead Clinical Supply Chain Pharmacist Allergy Therapeutics

Jane Twitchen

Executive Director, Head, Clinical Trial Accelerator Unit Biogen

Jane Twitchen graduated with a BSc in Medical Physics from the University of Exeter, UK and commenced her career with Covance, supporting a number of trials investigating radioisotope image optimisation. Having developed a keen interest in processes and systems, she then joined SAS, where she worked in the Alliances team collaborating with partners such as PWC, McKinsey and Accenture to define and implement solutions for pharmaceutical clients. During her tenure with SAS, Jane was also sponsored to complete her MBA. She proceeded to a number of software and service providers prior to joining Biogen in 2013, initially joining the Global Regulatory Affairs Quality and Operations team and moving to Global Clinical Operations in 2015. In her current role, Jane is Executive Director, Head of Biogen’s Clinical Trial Accelerator Unit and is responsible for delivery of Biogen’s goals for accelerated study start-up cycle time, in addition to embedding innovative operational delivery through the use of technology.

Leon Hooftman

Chief Medical Officer Barinthus Biotherapeutics

Lynette James

Vice President, Supply Chain & External Manufacturing Quell Therapeutics

Pietro Scalfaro

Senior Vice President, Head of Clinical Development Chief Medical Officer ENYO Pharma

Ridwaan Jhetam

Senior Vice President and Head of Worldwide Medical Affairs Hematology Bristol Myers Squibb

Ridwaan is the Senior Vice President and Head of Worldwide Medical Affairs Hematology at Bristol Myers Squibb. With more than 25 years of pharma industry experience, Ridwaan has a solid track record of delivery in Oncology & Hematology drug development, medical affairs & brand strategy, leading to successful product launches and optimal lifecycle management, including positive outcomes in regulatory engagement & reimbursement negotiations across healthcare systems in the US, Europe, and emerging markets.
Ridwaan is a clinical oncologist by training; qualifying as a medical doctor and with credentials in pharmacology and an MBA.
He has contributed over his career to the clinical development and commercialization of medicines as a strategic partner and through leading governance structures and high-performance teams to provide robust asset and portfolio strategies and evidence generation plans for various hematology, oncology, and supportive care products, including biologics, cytotoxics, targeted therapy, small molecules, immunotherapies, bispecific molecules, antibody-drug conjugates (ADCs), protein degraders, and CAR-T cell therapies. He has established scientific networks and collaborations with key opinion leaders, medical societies, cooperative groups, and patient advocacy organizations across the world.
He is also a visiting academic senior lecturer at King’s College London in the Department of Cancer and Pharmaceutical Sciences as well as at the Nelson Mandela University medical school. 
Ridwaan is driven by the opportunity to optimize early access to treatments and transform outcomes for patients across the world, together with oncology and hematology research and academic communities, with one focus and determination: to always keep patients at the heart of what he does.

Sarah Scorer

Senior Director, Head of Clinical Operations Tangram Therapeutics

Sarah is Head of Clinical Operations at Tangram Therapeutics. In this role, she leads the strategy, planning and delivery of Tangram’s clinical development programmes and builds the operational and governance frameworks needed to advance the company’s RNAi pipeline into and through the clinic. Sarah brings more than 20 years of global clinical development experience across rare, neurodegenerative and high-complexity diseases, spanning neurology, psychiatry, oncology, ophthalmology and rare disease. Prior to Tangram, she held senior clinical leadership roles at Biogen, where she served as Director, Country and Site Operations, leading multi-partner Phase I–IV programmes across academic, NHS and industry networks; at Shire (acquired by Takeda), where she provided scientific and operational leadership across late stage pipeline programs; and at Oxford Biomedica, a gene therapy company, where she led advanced-therapy and rare-disease studies across the EU and US. Sarah earned an MSc in Clinical Research from the University of Cardiff and a BSc in Biomedical Sciences from Newcastle University.

Suki Malhi

Head, Clinical Operations AtlaSyne

Teresa Nunez

Chief Medical Officer EpilepsyGTx

First name	Last name	Job title	Company name	Photo URL	Bio Position
Abhishek	Miglani	Head, Enterprise Platform, Senior Director	Veeva & Global Clinical Operations Technology, Astellas	https://proventainternational.com/wp-content/uploads/2025/07/Abhishek-Miglani-1.jpg	Abhishek Miglani is a visionary leader and industry thought leader advancing patient-centric innovation and access. He blends deep R&D acumen with a relentless focus on transforming healthcare through strategy, partnerships, and digital enablement—shaping the future of the pharmaceutical industry through impactful, ecosystem-wide leadership.
Alexander	Fetkovsky	CEO	SanaClis	https://proventainternational.com/wp-content/uploads/2026/09/Alexander-Fetkovsky.jpg	As CEO, Alexander Fetkovsky has overall responsibility for the planning and execution of strategic company initiatives and business partnering, in addition to global operational and financial oversight for multiple clinical programs and clinical trial supply/ warehouse operations. He previously held several C-level positions such as Senior Managing Partner and Member of the Board.
Charmaine	O’Neill	Vice President, Clinical Operations	Vantage Biosciences & Axovia Therapeutics	https://proventainternational.com/wp-content/uploads/2025/07/Charmaine-ONeill.jpg	Charmaine O’Neill brings over 30 years of diverse experience in Research and Development, currently supporting Axovia Therapeutics and Vantage Biosciences. She was most recently with Gyroscope Therapeutics, a Novartis company, and has held senior roles across pharma and biotech, including GSK, Aimmune Therapeutics, DSPE, PPD, Syneos, and hVivo. Charmaine has led global Phase I–III clinical programs to registration across multiple therapeutic areas, including ophthalmology, virology, diabetes, rare diseases, food allergy, and oncology. She holds BSc (Hons) degrees in Pharmacology and Psychology and is recognized for driving operational excellence in clinical trial delivery across early and late development.
David	Holman	Head, Clinical Program Management	30 Technology	https://proventainternational.com/wp-content/uploads/2026/08/David-Holman.jpg	David Holman, PhD, is a senior clinical development and operations leader with over 20 years of global experience spanning academia, biotechnology, pharma, and CROs. He holds a PhD in Neuroscience from the University of Bristol and has published peer-reviewed research in leading journals. David has held senior leadership roles at 30 Technology, PPD, and Gilead, leading clinical development and operations across respiratory, inflammation/immunology, neurology, and other therapeutic areas. His expertise spans early- to late-stage development, strategic program leadership, and cross-functional team management, with a particular focus on translating scientific strategy into successful clinical development and execution.
Deirdre	Flaherty	Vice President, Development Project Strategy & Clinical Operations	Alchemab Therapeutics Ltd	https://proventainternational.com/wp-content/uploads/2026/08/Deirdre-Flaherty.jpeg	Deirdre Flaherty is the Vice President of Development Project Strategy and Clinical Operations at Alchemab. She works with the product teams to drive the formation of strategy from candidate selection to clinical proof of concept as well as leading the clinical implementation of the strategy; she is simultaneously serving as the Program Lead for the company’s lead asset, ATLX-2847. Deirdre also maintains her own consulting business, LunAr PLPM, where she works with other start-up biotechs to help them in the important period between candidate molecule and clinical proof of concept. She has worked in the industry for almost 30 years with roles in Clinical Development, Portfolio Management, Program leadership and Project Management at Merck KGaA (formerly Merck Serono), GW Pharmaceuticals and Abcam. Deirdre holds a BA from Johns Hopkins University in Baltimore, Maryland, and an MBA from Columbia University in New York, New York.
Dr.	Apurba Mukherjee	Regional Medical Head, Intercontinental and JAK Regions	Ferring Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2026/09/Dr.-Apurba-Mukherjee.jpg	Dr. Apurba Mukherjee is a senior Medical Affairs leader with nearly two decades of experience across global and international markets. Based in London, he provides strategic and functional leadership to medical affairs teams across the Intercontinental and JAK regions, spanning oncology and multiple specialty therapeutic areas. With deep expertise in oncology, he has led major product launches, real-world evidence generation, global integrations, and medical affairs transformation initiatives. A published researcher in oncology and AI-driven healthcare, Apurba serves as Medical Lead for AI-based analytics in Global Medical Insights, focusing on translating complex data into actionable evidence, informed decision-making, and improved patient outcomes worldwide. I am very much looking forward to facilitating the discussion and exchanging perspectives with the delegates.
Dr.	Tony Lockett	Chief Medical Officer	Nevrargenics Ltd.	https://proventainternational.com/wp-content/uploads/2026/07/Tony-Lockett.jpg	Dr Tony Lockett is a physician, pharmaceutical medicine specialist and health economist with nearly four decades in clinical drug development. He is Senior Lecturer at King’s College London’s Centre for Pharmaceutical Medicine Research, where he leads the Clinical Drug Development MSc course, Medical Director of the Mark Sommerville Foundation, and Chief Medical Officer of Nevrargenics. Previously CMO at hVIVO, Avecia and Biatmospheric, he holds a PhD in economics and healthcare policy. A long-standing voice in rare disease policy, he chairs the FPM rare diseases expert group and advises the NHS rare disease forum and NICE on trial standards, and co-chairs King’s Research Ethics.
Eamonn	McArdle	Lead Clinical Supply Chain Pharmacist	Allergy Therapeutics	https://proventainternational.com/wp-content/uploads/2026/07/Kamal-Amin.jpg	Eamonn McArdle is a clinical supply chain leader with experience across global clinical development, NHS Supply Chain, and pharmaceutical operations. As Lead Clinical Supply Chain Pharmacist, he leads the delivery of compliant, patient-focused supply strategies for complex international clinical trials. With expertise spanning supply chain strategy, risk management, and operational excellence, Eamonn is passionate about building resilient and efficient supply networks. He is an active contributor to the profession through advisory board roles, thought leadership, and cross-industry collaboration.
Jane	Twitchen	Executive Director, Head, Clinical Trial Accelerator Unit	Biogen	https://proventainternational.com/wp-content/uploads/2022/03/Jane-Twitchen.jpg	Jane Twitchen graduated with a BSc in Medical Physics from the University of Exeter, UK and commenced her career with Covance, supporting a number of trials investigating radioisotope image optimisation. Having developed a keen interest in processes and systems, she then joined SAS, where she worked in the Alliances team collaborating with partners such as PWC, McKinsey and Accenture to define and implement solutions for pharmaceutical clients. During her tenure with SAS, Jane was also sponsored to complete her MBA. She proceeded to a number of software and service providers prior to joining Biogen in 2013, initially joining the Global Regulatory Affairs Quality and Operations team and moving to Global Clinical Operations in 2015. In her current role, Jane is Executive Director, Head of Biogen’s Clinical Trial Accelerator Unit and is responsible for delivery of Biogen’s goals for accelerated study start-up cycle time, in addition to embedding innovative operational delivery through the use of technology.
Leon	Hooftman	Chief Medical Officer	Barinthus Biotherapeutics	https://proventainternational.com/wp-content/uploads/2026/07/Leon-Hooftman.jpg
Lynette	James	Vice President, Supply Chain & External Manufacturing	Quell Therapeutics	https://proventainternational.com/wp-content/uploads/2026/06/Lynette-James.jpg	Lynette James is a biotechnology executive with more than 20 years of international leadership experience spanning Cell & Gene Therapy, supply chain, patient supply operations, external manufacturing and clinical operations. She is currently Vice President, Supply Chain & External Manufacturing at Quell Therapeutics, where she leads global supply chain, patient supply and external manufacturing for the company’s regulatory T-cell therapy portfolio. Previously, Lynette was Vice President, Patient Supply Operations at Achilles Therapeutics and held senior Clinical Operations roles at Gilead Sciences. Lynette is recognised for building high-performing teams, transforming complex operations into scalable and resilient organisations, and successful
Pietro	Scalfaro	Senior Vice President, Head of Clinical Development Chief Medical Officer	ENYO Pharma	https://proventainternational.com/wp-content/uploads/2026/06/Pietro-Scalfaro-1.jpg	Pietro Scalfaro, MD, MBA, is a physician executive and Chief Medical Officer with more than 25 years of experience across pharmaceutical, biotechnology, and healthcare organizations. He specializes in clinical development, clinical operations, and data-driven monitoring of complex drug development programs. As Chief Medical Officer at ENYO Pharma, he oversees program strategy, clinical trial design, execution, and CRO management from non-clinical development through early-phase human studies. Previously, he served as Chief Project Officer and Business Unit Director at Debiopharm, where he built a clinical operations department and led multiple R&D programs. He has also held founder, advisory, and medical roles supporting innovative healthcare and biotechnology companies. Dr. Scalfaro holds an MD and an Executive MBA from the University of Lausanne and is multilingual in English, Swiss-German, French, and Italian.
Ridwaan	Jhetam	Senior Vice President and Head of Worldwide Medical Affairs Hematology	Bristol Myers Squibb	https://proventainternational.com/wp-content/uploads/2026/06/Ridwaan-Jhetam.jpg	Ridwaan is the Senior Vice President and Head of Worldwide Medical Affairs Hematology at Bristol Myers Squibb. With more than 25 years of pharma industry experience, Ridwaan has a solid track record of delivery in Oncology & Hematology drug development, medical affairs & brand strategy, leading to successful product launches and optimal lifecycle management, including positive outcomes in regulatory engagement & reimbursement negotiations across healthcare systems in the US, Europe, and emerging markets. Ridwaan is a clinical oncologist by training; qualifying as a medical doctor and with credentials in pharmacology and an MBA. He has contributed over his career to the clinical development and commercialization of medicines as a strategic partner and through leading governance structures and high-performance teams to provide robust asset and portfolio strategies and evidence generation plans for various hematology, oncology, and supportive care products, including biologics, cytotoxics, targeted therapy, small molecules, immunotherapies, bispecific molecules, antibody-drug conjugates (ADCs), protein degraders, and CAR-T cell therapies. He has established scientific networks and collaborations with key opinion leaders, medical societies, cooperative groups, and patient advocacy organizations across the world. He is also a visiting academic senior lecturer at King’s College London in the Department of Cancer and Pharmaceutical Sciences as well as at the Nelson Mandela University medical school. Ridwaan is driven by the opportunity to optimize early access to treatments and transform outcomes for patients across the world, together with oncology and hematology research and academic communities, with one focus and determination: to always keep patients at the heart of what he does.
Sarah	Scorer	Senior Director, Head of Clinical Operations	Tangram Therapeutics	https://proventainternational.com/wp-content/uploads/2026/07/Sarah-Scorer.jpg	Sarah is Head of Clinical Operations at Tangram Therapeutics. In this role, she leads the strategy, planning and delivery of Tangram’s clinical development programmes and builds the operational and governance frameworks needed to advance the company’s RNAi pipeline into and through the clinic. Sarah brings more than 20 years of global clinical development experience across rare, neurodegenerative and high-complexity diseases, spanning neurology, psychiatry, oncology, ophthalmology and rare disease. Prior to Tangram, she held senior clinical leadership roles at Biogen, where she served as Director, Country and Site Operations, leading multi-partner Phase I–IV programmes across academic, NHS and industry networks; at Shire (acquired by Takeda), where she provided scientific and operational leadership across late stage pipeline programs; and at Oxford Biomedica, a gene therapy company, where she led advanced-therapy and rare-disease studies across the EU and US. Sarah earned an MSc in Clinical Research from the University of Cardiff and a BSc in Biomedical Sciences from Newcastle University.
Suki	Malhi	Head, Clinical Operations	AtlaSyne	https://proventainternational.com/wp-content/uploads/2026/06/Suki-Malhi.jpeg	Suki Malhi is a highly credible and innovative clinical development executive with a breadth and depth of knowledge to lead biopharmaceutical/pharmaceutical development operations from phase I to IV (registration through post-marketing commitments). Currently leading GRIN Therapeutics on a global pivotal programme with strategic recruitment strategy, KOL engagement, and operational efficiency on an ultra-rare disease. Previously held leadership roles at AstraZeneca, Genzyme, Takeda, Biomarin, Sage Therapeutics, and Wave Lifesciences.
Teresa	Nunez	Chief Medical Officer	EpilepsyGTx	https://proventainternational.com/wp-content/uploads/2022/05/avatar.jpg

Abhishek Miglani, Alexander Fetkovsky, Charmaine O’Neill, David Holman, Deirdre Flaherty, Dr. Apurba Mukherjee, Dr. Tony Lockett, Eamonn McArdle, Jane Twitchen, Leon Hooftman, Lynette James, Pietro Scalfaro, Ridwaan Jhetam, Sarah Scorer, Suki Malhi, Teresa Nunez

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Clinical Trials Europe

Clinical Operations & Clinical Trial Supply Chain Strategy Meeting Europe 2025

&

Strategy Meeting Europe 2026

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Crowne Plaza London Docklands

Fresh Clinical Operations Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Facilitators

Abhishek Miglani

Alexander Fetkovsky

Charmaine O’Neill

David Holman

Deirdre Flaherty

Dr. Apurba Mukherjee

Dr. Tony Lockett

Eamonn McArdle

Jane Twitchen

Leon Hooftman

Lynette James

Pietro Scalfaro

Ridwaan Jhetam

Sarah Scorer

Suki Malhi

Teresa Nunez

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable

Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Networking / 1-1 Meetings

Networking / 1-1 Meetings

Roundtable (Solution)

Roundtable ( Pharma/Biotech )

Sponsor

Roundtable ( Pharma/Biotech )

Roundtable ( Pharma/Biotech )

Networking Lunch

Networking / 1-1 Meetings

Networking / 1-1 Meetings

Afternoon Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

CLOSING PANEL DISCUSSION

Drinks & Canapes Reception

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our 2026 Sponsors

Our Lead Sponsor

Our Partnering Sponsors

Become an official strategy meeting partner

Testimonials

Hotel & Venue

Crowne Plaza London Docklands

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Crowne Plaza London Docklands